-
Oil prices fall after Trump hails 'good' talks with Iran
-
Tata turmoil shines light on India succession woes
-
AI political ads warp reality ahead of US midterms
-
World Cup 'not enough' as Spain begin next chapter
-
Kenneth Branagh embraces action hero role -- to get in shape
-
Meta acts against 3.7 mn scammers' accounts with Singapore police help
-
'New one' Klopp promises fresh approach as Germany reign begins
-
Australia PM says draft social media rules about taking back control
-
Milne returns to New Zealand squad for India T20 series
-
Voting opens in Alaska's annual Fat Bear Week
-
US-led Americas coalition backs sanctions against crime groups
-
MLS coach axed for telling female ref 'It's a man's game'
-
'Star Wars' fans and art lovers line up for new Lucas museum
-
US refuses to give Sudan's de facto leader visa for UN
-
Trump renames AI 'super intelligence' as leaders jostle over dangers
-
Man City hold Bayern to start Women's Champions League, Arsenal win late
-
Oil prices retreat as markets welcome US-Iran talks
-
Trump threatens Iran with 'hell' but reveals fresh talks
-
US refusing to give Sudan's de facto leader visa for UN: diplomatic sources, UN
-
Trump signs security deal with Greenland, Denmark at UN
-
Macron urges world to choose UN over 'law of the jungle'
-
Trump threatens Iran with 'hell' but unveils fresh talks
-
All-rounder Jacks stars as England beat Sri Lanka in 1st ODI
-
Chile's Atacama Desert blossoms with life after El Nino rains
-
Man City peg back Bayern to start Women's Champions League
-
Sri Lanka hands 220-year jail terms to 15 convicted of Easter bombings
-
Trump beats 'America first' drum at UN as allies tread carefully
-
Typhoon Dujuan leaves 7 dead in Japan from landslides, flooding: media
-
Snedeker backs Spaun for Ryder Cup after Presidents snub
-
Ganna and Borghini lead Italy to mixed relay gold at cycling worlds
-
French prosecutors probe secret filming of women with smart glasses
-
Drug cocktail killed former child star Hayden Panettiere: coroner
-
Trump renames AI "super intelligence," rejects international oversight
-
Moldova declares energy, water emergency
-
Trump rejects international regulation of AI
-
French Holocaust denier jailed for eight months
-
How is the EU approaching record fuel prices?
-
Oil prices slide, AI stock buzz fades
-
Sri Lanka's Colombage strikes on debut as England dismissed for 265 in first ODI
-
Trump threatens to 'annihilate' Iran in bombastic UN speech
-
Hurricane Polo strengthens to top category 5 off Mexico
-
Prada's skirts take centre stage as Milan Fashion Week begins
-
11 hurt as teen opens fire outside school in western Turkey
-
Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome
-
UN chief says 'Big Oil' treats atmosphere as open sewer
-
Brazil's Flavio Bolsonaro turns scandal into poll gains
-
Tunisia says 2026 summer hottest on record
-
Republican senator seeks probe of Trump Jr Russian-funded wedding
-
England's Rashid out of Sri Lanka ODIs with hand injury
-
Memoir by Diana's brother goes on sale after rocking UK monarchy
Independent Evaluation Confirms Breakthrough Performance of BioLargo's Cellinity Battery Technology for Grid-Scale Energy Storage
WESTMINSTER, CALIFORNIA / ACCESS Newswire / June 18, 2025 / BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that a third-party evaluation has confirmed key advantages for its Cellinity battery technology's use in grid-scale battery energy storage applications.
The evaluation was conducted by U.S. BESS Corporation (www.usbesscorp.com), an expert provider of advanced energy storage solutions for critical infrastructure applications spanning utilities, defense, microgrids, and heavy industry.
U.S. BESS senior technical staff performed an examination of Cellinity's design and assembly protocols, inspection of testing infrastructure, review of data from test results, and an assessment of methodologies used for performance characterization, concluding that the following performance characteristics exclusive of any auxiliary systems are supported by their observations and are reasonably representative of the current Cellinity cell's demonstrated behavior:
Open circuit voltage: > 4.2 V
Operating temperature range: from 120°C to 250°C
Energy density: > 500 Wh/kg (calculated based on active material)
Power density: > 500 mW/cm3 (maximum observed value of 1579 W/kg at 230°C)
Charge capacity: Cell can be charged to 100% of theoretical capacity
Charge/discharge efficiency: ~100%
Energy efficiency: 95% at 230°C; 87% at 120°C
Self-discharge: No measurable self-discharge observed over test durations
Thermal cycling durability: Performance unaffected after repeated cycling
U.S. BESS Corp further concluded that it is reasonable to claim that a) the cell would not experience any thermal runaway, b) materials of construction are commonly available and can be domestically sourced, c) the cell does not contain any rare earth elements, and d) cell components are fully recyclable.
A Market Ready for Disruption
The global demand for grid-scale energy storage is rapidly growing to meet the rising loads driven by artificial intelligence, decarbonization mandates, and accelerated adoption of renewables. In 2024 alone, the U.S. Energy Information Administration (www.eia.gov) reported a 66% increase in U.S. battery energy storage capacity. While lithium-ion batteries currently dominate the market, they present known challenges: fire risks from thermal runaway, efficiency losses over time, and sourcing constraints related to rare and critical minerals.
BioLargo's Cellinity battery technology (www.biolargoenergy.com) overcomes these limitations by leveraging novel materials and architecture to deliver both exceptional thermal performance and operational efficiencywithout relying on rare earth elements.
Validation Supports Commercial Pathway
The U.S. BESS report concludes: "Based on our inspection and the evidence provided, U.S. BESS finds that the Cellinity Cell demonstrates a sufficient performance profile, with strong indications of high thermal stability, efficiency, energy and power density, and material sustainability, to suggest further investment in testing and commercialization. These attributes position this technology as a potential solution for critical gaps in grid-scale energy storage markets."
Randall Moore, Chief Technology Officer at BioLargo Energy Technologies, Inc., commented, "Our work to scale up the cell design, refine manufacturing techniques, and integrate cells into a functional module for commercial scale testing is underway."
CEO, Dennis P. Calvert commented, "We do not know of any long duration energy storage technology that can match Cellinity's technical claims for cost effective performance and safety. This third-party evaluation is an important piece of the puzzle for our business plan to bring Cellinity to the world through manufacturing joint ventures. We have several of these in development with potential partners and look forward to sharing more intel about those soon."
About U.S. BESS Corp
U.S. BESS Corp is a U.S.-based company that provides energy storage solutions for a wide range of applications, including utilities, industrial needs, microgrids and defense. With decades of combined experience in battery engineering, microgrid deployment, system-level integration, and manufacturing, the company's leadership team is uniquely qualified in the battery energy storage system industry. U.S. BESS is creating the most advanced and secure battery management system and building the largest domestic battery supply in the USA.
U.S. BESS Corp Contact Information
Mark Hagedorn
CEO, U.S. BESS Corp.
503-720-9569
About BioLargo, Inc.
BioLargo, Inc. (OTCQX:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.
BioLargo Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.
SOURCE: BioLargo, Inc
View the original press release on ACCESS Newswire
M.Robinson--AT